| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
LNP Lipid-7 does not have a defined pharmacological target; it is a formulation excipient for lipid nanoparticles. As a lipid (likely a cationic or ionizable lipid), it is incorporated into LNP formulations to improve their stability and enhance drug delivery efficiency. The lipid helps to encapsulate and protect nucleic acid cargo (e.g., mRNA, siRNA) from degradation, facilitates cellular uptake, and promotes endosomal escape. LNP Lipid-7 is designed to enable efficient delivery of genetic material to target cells.
|
|---|---|
| ln Vitro |
In vitro, LNP Lipid-7 is used as a component in LNP formulations to deliver nucleic acids to cells in culture. LNPs containing Lipid-7 demonstrate efficient encapsulation of mRNA or siRNA, resulting in successful transfection and gene expression or gene silencing in various cell lines. The lipid is often used together with LNP Lipid-6 in formulations. These LNPs protect the nucleic acid cargo from RNase degradation and facilitate cellular uptake, making them valuable for studying gene delivery mechanisms and for developing cell-based assays.
|
| ln Vivo |
In vivo, LNP Lipid-7 is used to formulate LNPs for the delivery of RNA-based therapeutics in animal models. LNPs containing Lipid-7 can be administered via intravenous injection, leading to efficient delivery of nucleic acid cargo to target tissues such as the liver and spleen. The ability to protect mRNA from degradation and facilitate cellular uptake makes LNP Lipid-7 suitable for vaccine applications and gene therapy research. It is particularly relevant for the development of mRNA vaccines and siRNA-based treatments.
|
| Enzyme Assay |
The standard formulation protocol for LNPs containing LNP Lipid-7 involves mixing Lipid-7 with helper lipids (e.g., DSPC, cholesterol, and PEG-lipid) in ethanol at defined molar ratios (e.g., Lipid-7 : cholesterol : DSPC : PEG-lipid = 50:38.5:10:1.5). The lipid mixture is combined with an aqueous solution containing nucleic acid (mRNA or siRNA) at a controlled flow rate using a microfluidic device or T-junction mixing, resulting in spontaneous LNP formation. The resulting LNPs are dialyzed against PBS to remove ethanol and concentrated by ultrafiltration. Particle size (typically 70-150 nm), polydispersity index (PDI <0.2), and zeta potential are measured by DLS. Encapsulation efficiency is determined using a RiboGreen assay, which measures unencapsulated nucleic acid.
|
| Cell Assay |
For in vitro studies, LNPs are diluted in culture medium and added to cells (e.g., HEK293, HeLa, or primary hepatocytes). After 24-48 hours, transfection efficiency is assessed by measuring reporter gene expression (e.g., luciferase, GFP) or target gene knockdown (by qPCR).
|
| Animal Protocol |
For in vivo studies, LNP Lipid-7-based LNPs are diluted in PBS or sucrose buffer and administered to rodents via intravenous injection (tail vein) at doses of 0.1-5 mg/kg (based on nucleic acid content). Blood is collected at various time points to measure nucleic acid concentration or protein expression. Tissue distribution is assessed by quantifying nucleic acid content in organs (liver, spleen, lungs) by qPCR or by imaging of fluorescently labeled cargo. For vaccine studies, animals are immunized with LNP-encapsulated mRNA encoding an antigen, and immune responses are measured by ELISA or ELISpot.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for LNP Lipid-7 as a free lipid are not available, as it is always formulated into LNPs. The molecular weight of LNP Lipid-7 is 615.02, and the molecular formula is C41H74O3. It is a cationic or ionizable lipid and is soluble in DMSO at 100 mg/mL. For in vivo use, a formulation with DMSO and co-solvents is used. LNP Lipid-7 should be stored at -20degC as a powder or in solution. In solvent, it should be stored at -80degC for 6 months or -20degC for 1 month.
|
| Toxicity/Toxicokinetics |
Toxicological data for LNP Lipid-7 alone are limited. As a component of LNPs, its safety profile is formulation-dependent. Cationic and ionizable lipids at high doses may cause transient elevations in liver enzymes (ALT/AST) and pro-inflammatory cytokines (IL-6, TNF-alpha), which are typically dose-dependent and reversible. In preclinical studies, LNP Lipid-7-containing LNPs are generally well tolerated at therapeutic doses. Comprehensive toxicology studies are formulation-specific.
|
| References | |
| Additional Infomation |
LNP Lipid-7 is a research-grade compound and is not approved for clinical use. It is a lipid component used exclusively for LNP formulation in drug delivery research. It is used in combination with LNP Lipid-6 and other helper lipids to prepare LNPs for the delivery of nucleic acid therapeutics. LNP Lipid-7 is relevant for the development of mRNA vaccines, gene therapies, and other nucleic acid-based medicines. The CAS number is 1190203-55-4. Store at -20degC as a powder, protected from light and moisture.
|
| Molecular Formula |
C41H74O3
|
|---|---|
| Molecular Weight |
615.024473667145
|
| Exact Mass |
614.563
|
| CAS # |
1190203-55-4
|
| PubChem CID |
58275668
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
14.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
32
|
| Heavy Atom Count |
44
|
| Complexity |
659
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCO)CCCCCCCC/C=C\C/C=C\CCCCC
|
| InChi Key |
XGGMAKMFLSZTIY-MAZCIEHSSA-N
|
| InChi Code |
InChI=1S/C41H74O3/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-36-41(43-39-40(44-41)35-38-42)37-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h11-14,17-20,40,42H,3-10,15-16,21-39H2,1-2H3/b13-11-,14-12-,19-17-,20-18-
|
| Chemical Name |
2-[2,2-bis[(9Z,12Z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]ethanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6260 mL | 8.1298 mL | 16.2596 mL | |
| 5 mM | 0.3252 mL | 1.6260 mL | 3.2519 mL | |
| 10 mM | 0.1626 mL | 0.8130 mL | 1.6260 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
